@article{41fa74eed02e410aa25d76b1f237ca77,
title = "Author reply",
abstract = "[No abstract available]",
keywords = "adalimumab, ceftazidime, corticosteroid, interleukin 12, natalizumab, rain, tumor necrosis factor alpha, amoxicillin plus clavulanic acid, antiinfective agent, antirheumatic agent, monoclonal antibody, ankylosing spondylitis, antibiotic therapy, bacteremia, biological therapy, blood culture, Burkholderia pseudomallei, chronic lung disease, corticosteroid therapy, disease association, disease predisposition, drug megadose, fever, gardening, headache, host resistance, human, immunosuppressive treatment, immunotherapy, inoculation, lethargy, Letter, melioidosis, nausea, nonhuman, postmarketing surveillance, priority journal, progressive multifocal leukoencephalopathy, psoriasis, risk factor, Arthritis, Psoriatic, male, Amoxicillin-Potassium Clavulanate Combination, Anti-Infective Agents, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Humans, Male, Melioidosis",
author = "Commons, {R. J.} and R. Hannah and Currie, {B. J.}",
year = "2015",
month = may,
doi = "10.1111/imj.12744",
language = "English",
volume = "45",
pages = "591--591",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "John Wiley & Sons",
number = "5",
}